CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Teicoplanin as an anti-methicillin resistant staphylococcus aureus agent in infections of severely poisoned intensive care unit patients/Tehran- Iran
Authors
B.B. Barari
M.R. Hemami
+5 more
S. Kamalbeik
A. Mahdavinejad
P. Razi
A. Salimi
H. Talaie
Publication date
1 January 2013
Publisher
L'Ateneo Parmense
Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is related to high morbidity and mortality. Teicoplanin is a semi synthetic glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Our objective is the evaluation of efficacy and safety of Teicoplanin in MRSA infections among severely poisoned intensive care unit (ICU) patients.Methods: During a 6 months period, in a prospective cross sectional study, 54 eligible patients were recruited from among 80 who were clinically suspicious for MRSA infections. The efficacy and safety ofTeicoplanin by loding dose of 6 mg/kg (maximum 400 mg per dose) for three loading doses 12 hours apart and then every 24 hours was evaluated 5 times.The clinical findings, laboratory data, and bacteriologic responses were categorized as cure, improvement and failure. Results: The mean(SD) age was 36.3(13.3) years. 75.9 were male. Suicidal attempts were recorded in 63. The most common poisoning was TCAs, BZDs, tramadol and opium. 94.4 were unconscious and under mechanical ventilation. Tracheal cultures were positive in 98.1 by VAP diagnosis. ICU length of stay was between 4-54 days. Total clinical effectiveness was 90.4, and failure 9.6. Mortality rate was 9/54 (16.6 ). On the fourth visit, the adverse effects included: rash (11.10), anemia (36.17), nephrotoxicity (17.02) and thrombocytopenia < 150000 (100). Other side effects such as: leucopenia, severe thrombocytopenia (< 50000), pancytopenia and red man syndrome were not detected.Conclusions: Teicoplanin can be suggested for use in forMRSA infections among severely poisoned patient, based on its efficacy, safety, half life and tolerance. © Mattioli 1885
Similar works
Full text
Available Versions
eprints Iran University of Medical Sciences
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.iums.ac.ir:9827
Last time updated on 10/10/2019